Drugs / Vonsetamig
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06975787 | Dec 2025 → Sep 2029 expected | lupus nephritis | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05092347 | Aug 2022 → Nov 2027 expected | chronic kidney disease | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vonsetamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05092347 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314788 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT05092347 ↗ |